← Back to home

BREAST NEOPLASMS (INCLUDING ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA MUTATION)

Clinical trials for BREAST NEOPLASMS (INCLUDING ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA MUTATION) explained in plain language.

Never miss a new study

Get alerted when new BREAST NEOPLASMS (INCLUDING ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA MUTATION) trials appear

Sign up with your email to follow new studies for BREAST NEOPLASMS (INCLUDING ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA MUTATION), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Alpelisib's Long-Term safety tracked in PIK3CA patients

Disease control Not yet recruiting

This study provides continued access to alpelisib for people who are already benefiting from it in a previous Novartis trial. It focuses on tracking long-term safety, including any side effects, in participants with PIK3CA-related overgrowth spectrum or certain breast cancers. Pa…

Matched conditions: BREAST NEOPLASMS (INCLUDING ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA MUTATION)

Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Jul 02, 2026 07:00 UTC

BREAST NEOPLASMS (INCLUDING ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA MUTATION)

Get alerted when new BREAST NEOPLASMS (INCLUDING ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA MUTATION) trials appear

Alpelisib's Long-Term safety tracked in PIK3CA patients